BR9916398A - Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente - Google Patents

Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente

Info

Publication number
BR9916398A
BR9916398A BR9916398-5A BR9916398A BR9916398A BR 9916398 A BR9916398 A BR 9916398A BR 9916398 A BR9916398 A BR 9916398A BR 9916398 A BR9916398 A BR 9916398A
Authority
BR
Brazil
Prior art keywords
diseased tissue
treatment
agent
radiosensitization
radiosensitizing
Prior art date
Application number
BR9916398-5A
Other languages
English (en)
Inventor
H Craig Dees
Timothy C Scott
John T Smolik
Eric A Wachter
Original Assignee
Photogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photogen Inc filed Critical Photogen Inc
Publication of BR9916398A publication Critical patent/BR9916398A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Saccharide Compounds (AREA)

Abstract

"AGENTE RADIOSSENSIBILIZADOR PARA O TRATAMENTO DE TECIDO DOENTE USANDO-SE RADIOSSENSIBILIZAçãO OU RADIAçãO IONIZANTE, E, MéTODO DE TRATAMENTO DE TECIDO DOENTE" Agentes fototerapêuticos de alta energia ou um agente radiossensibilizador compreendido de um xanteno halogenado ou um agente que exibe uma preferência por concentração em estruturas biologicamente sensíveis em tecido doente e métodos de tratamento e de formação de imagem que usam agentes radiossensibilizadores em tecido doente.
BR9916398-5A 1998-12-21 1999-12-16 Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente BR9916398A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/216,787 US6331286B1 (en) 1998-12-21 1998-12-21 Methods for high energy phototherapeutics
PCT/US1999/030156 WO2000037927A1 (en) 1998-12-21 1999-12-16 High energy phototherapeutic agents

Publications (1)

Publication Number Publication Date
BR9916398A true BR9916398A (pt) 2001-09-11

Family

ID=22808515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916398-5A BR9916398A (pt) 1998-12-21 1999-12-16 Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente

Country Status (14)

Country Link
US (2) US6331286B1 (pt)
EP (1) EP1192450B1 (pt)
JP (1) JP3735770B2 (pt)
KR (1) KR20010089658A (pt)
CN (1) CN1331797A (pt)
AR (1) AR021967A1 (pt)
AU (1) AU2368700A (pt)
BR (1) BR9916398A (pt)
CA (1) CA2352094C (pt)
ES (1) ES2526460T3 (pt)
HK (1) HK1041726A1 (pt)
IL (1) IL143468A0 (pt)
TW (1) TWI231368B (pt)
WO (1) WO2000037927A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060095097A1 (en) * 1996-10-30 2006-05-04 Provectus Devicetech, Inc. Treatment of pigmented tissue using optical energy
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7036516B1 (en) 1996-10-30 2006-05-02 Xantech Pharmaceuticals, Inc. Treatment of pigmented tissues using optical energy
US7390668B2 (en) * 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US8470296B2 (en) * 1998-12-21 2013-06-25 Provectus Pharmatech, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US7384623B1 (en) 1998-12-21 2008-06-10 Provectus Pharmatech, Inc. High energy phototherapeutic agents
US20020001567A1 (en) * 1998-12-21 2002-01-03 Photogen, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
AR022404A1 (es) * 1999-01-25 2002-09-04 Photogen Inc Metodo y agentes para la terapia de radiacion mejorada
CA2380805C (en) * 1999-08-13 2010-04-13 Photogen, Inc. Improved topical medicaments and methods for photodynamic treatment of disease
GB0017084D0 (en) * 2000-07-13 2000-08-30 Univ Bristol Inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel
KR20020050279A (ko) * 2000-09-14 2002-06-26 요트.게.아. 롤페즈 데이터 아이템을 저장하기 위한 방법 및 시스템
US20020107281A1 (en) * 2000-09-22 2002-08-08 Photogen, Inc. Phototherapeutic and chemotherapeutic immunotherapy against tumors
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
DE60318561T2 (de) * 2002-04-02 2009-01-08 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
US7981928B2 (en) * 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
US20050053895A1 (en) 2003-09-09 2005-03-10 The Procter & Gamble Company Attention: Chief Patent Counsel Illuminated electric toothbrushes emitting high luminous intensity toothbrush
KR101125678B1 (ko) 2004-02-06 2012-03-28 롬 앤드 하스 일렉트로닉 머트어리얼즈, 엘.엘.씨. 개선된 이미지화 조성물 및 방법
US7144676B2 (en) 2004-02-06 2006-12-05 Rohm And Haas Electronic Materials Llc Imaging compositions and methods
US7977026B2 (en) 2004-02-06 2011-07-12 Rohm And Haas Electronic Materials Llc Imaging methods
US20050175941A1 (en) 2004-02-06 2005-08-11 Rohm And Hass Electronic Materials, L.L.C. Imaging composition and method
CA2570687C (en) * 2004-06-10 2013-07-09 Xantech Pharmaceuticals, Inc. Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents
WO2006037081A2 (en) * 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
WO2006055960A2 (en) * 2004-11-20 2006-05-26 Scenterra, Inc. Device for emission of high frequency signals
US7280078B2 (en) 2004-11-20 2007-10-09 Scenterra, Inc. Sensor for detecting high frequency signals
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
US20090104212A1 (en) * 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
US8530675B2 (en) 2009-09-18 2013-09-10 Provectus Pharmaceuticals, Inc. Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (rose bengal) and related xanthenes
US9273022B2 (en) 2009-09-18 2016-03-01 Provectus Pharmaceuticals, Inc. Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes
US9642687B2 (en) 2010-06-15 2017-05-09 The Procter & Gamble Company Methods for whitening teeth
RU2533267C1 (ru) * 2013-10-07 2014-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТГМУ Минздрава России) Способ фотон-захватной терапии опухолей
AU2018375425B2 (en) 2017-11-29 2023-03-02 Provectus Pharmatech, Inc. Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
AU2019268353B2 (en) 2018-05-16 2023-05-04 Provectus Pharmatech, Inc. In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
CN111317731A (zh) * 2018-12-17 2020-06-23 中山大学 9-(2-羧基苯基)呫吨类化合物制备fto抑制剂及其治疗作用
US11419844B2 (en) 2019-11-19 2022-08-23 Provectus Pharmatech, Inc. Halogenated xanthene composition and method for treating hematologic cancers
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
US11975106B2 (en) 2020-03-26 2024-05-07 Provectus Pharmatech, Inc. Uses of halogenated xanthenes in oncology and virology

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868950A (en) 1970-09-24 1975-03-04 Yoshio Kato Body treating apparatus
US4066650A (en) 1971-02-11 1978-01-03 Egyud Laszlo G Keto-aldehyde-amine addition products and method of making same
US3986513A (en) 1976-01-29 1976-10-19 Joseph Lester Stuhl Apparatus for irradiating the skin
IE47132B1 (en) 1977-08-19 1983-12-28 Roche Products Ltd Novel nitroimidazoles and pharmaceutical preparations containing these as well as their manufacture
US4172979A (en) 1978-06-15 1979-10-30 Morrison Richard A Method and apparatus for automatically providing radiation therapy treatment conforming to a desired volume of tissue
US4282232A (en) 1979-04-26 1981-08-04 Research Corporation Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
US4371540A (en) 1979-09-14 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells
US4444189A (en) 1981-12-21 1984-04-24 Seiverd Paul J Phototherapy booth
US4462992A (en) 1982-02-08 1984-07-31 Research Corporation Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
US4490543A (en) * 1982-11-12 1984-12-25 University Of Northern Iowa Foundation Low toxicity radiation sensitizer
US4691332A (en) 1983-03-14 1987-09-01 American Science And Engineering, Inc. High energy computed tomography
US4599227A (en) 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4681091A (en) 1984-08-03 1987-07-21 Picker Donald H Combination modality cancer therapy
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
HU195487B (en) 1985-06-04 1988-05-30 Egyt Gyogyszervegyeszeti Gyar Process for producing quinoline derivatives
FR2596989B1 (fr) 1986-04-14 1990-05-18 Air Liquide Produit de radiosensibilisation des tissus biologiques en radiotherapie
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5026694A (en) 1987-04-13 1991-06-25 The British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
CA1329206C (en) 1987-06-10 1994-05-03 Tsutomu Kagiya Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same
US5304654A (en) 1987-06-10 1994-04-19 Yasunori Nishijima Fluorine-containing nitroimidazole compounds
US4856528A (en) 1987-06-26 1989-08-15 John Hopkins University Tumor volume determination
US4957481A (en) 1987-10-01 1990-09-18 U.S. Bioscience Photodynamic therapeutic technique
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5053006A (en) 1988-04-19 1991-10-01 Watson Brant D Method for the permanent occlusion of arteries
US4897423A (en) 1988-08-02 1990-01-30 Merck & Co. Inc. Dinitrobenzenesulfonamides
US4880821A (en) 1988-08-17 1989-11-14 Merck & Co., Inc. α-nitroalkylnitrobenzenesulfonamides
US5036096A (en) 1988-11-25 1991-07-30 Warner-Lambert Company Aziridino derivatives of nitroimidazoles and pharmaceutical compositions of selected derivatives
US4954515A (en) 1988-11-25 1990-09-04 Warner-Lambert Company Haloalkylaminomethyl-2-nitro-1H-imidazoles
US5036089A (en) 1988-11-25 1991-07-30 Warner-Lambert Company 2-oxazolidinone derivatives of nitroimidazoles and pharmaceutical compositions useful as sensitizing agents
IL92597A0 (en) 1988-12-14 1990-08-31 Yasunori Nishijima President K Novel fluorine-containing 2-nitroimidazole derivatives and radiosensitizer comprising the same
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5641764A (en) 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
US5008907A (en) 1989-05-31 1991-04-16 The Regents Of The University Of California Therapy x-ray scanner
US4973848A (en) 1989-07-28 1990-11-27 J. Mccaughan Laser apparatus for concurrent analysis and treatment
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
JP2626727B2 (ja) 1990-01-26 1997-07-02 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤
US5147652A (en) 1990-07-03 1992-09-15 Cell Research Corporation Autobiotics and their use in eliminating nonself cells in vivo
US5282781A (en) 1990-10-25 1994-02-01 Omnitron International Inc. Source wire for localized radiation treatment of tumors
US5149801A (en) 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5654423A (en) 1990-11-21 1997-08-05 Regents Of The University Of California Boronated metalloporphyrine and therapeutic methods
US5294715A (en) 1991-02-01 1994-03-15 University Of Pittsburgh Acridine-intercalator based hypoxia selective cytotoxins
US5128139A (en) 1991-02-15 1992-07-07 Nu Skin International, Inc. Composition containing liposome-entrapped grapefruit seed extract and method for making
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
MX9304399A (es) 1992-07-31 1994-02-28 Warner Lambert Co Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5556992A (en) * 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
US5935942A (en) * 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature
US5602142A (en) 1994-12-21 1997-02-11 Evanston Hospital Corporation DNA-affinic hypoxia selective cytotoxins
US5576013A (en) 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
US5700825A (en) 1995-03-31 1997-12-23 Florida State University Radiosensitizing diamines and their pharmaceutical preparations
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5756726A (en) 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
IT1275571B (it) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US5832931A (en) 1996-10-30 1998-11-10 Photogen, Inc. Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
US5827186A (en) 1997-04-11 1998-10-27 Light Sciences Limited Partnership Method and PDT probe for minimizing CT and MRI image artifacts
CA2348536A1 (en) 1998-10-29 2000-05-11 The General Hospital Corporation Radiodense compositions

Also Published As

Publication number Publication date
KR20010089658A (ko) 2001-10-08
EP1192450B1 (en) 2014-12-03
HK1041726A1 (zh) 2002-07-19
CN1331797A (zh) 2002-01-16
CA2352094A1 (en) 2000-06-29
JP2002533355A (ja) 2002-10-08
JP3735770B2 (ja) 2006-01-18
EP1192450A4 (en) 2003-05-21
AR021967A1 (es) 2002-09-04
CA2352094C (en) 2010-12-07
US20050207976A1 (en) 2005-09-22
EP1192450A1 (en) 2002-04-03
AU2368700A (en) 2000-07-12
ES2526460T3 (es) 2015-01-12
US6331286B1 (en) 2001-12-18
TWI231368B (en) 2005-04-21
IL143468A0 (en) 2002-04-21
WO2000037927A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
BR9916398A (pt) Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
BR9914969A (pt) Métodos para formar imagem, tratar e localizar tecido doente, e, dispositivo integrado de formação de imagem e de tratamento
SE9404196D0 (sv) New antithrombotic formulation
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BR9915080A (pt) Fonte radioativa para uso em braquiterapia, métodos para a preparação de uma fonte radioativa e para tratamento de uma condição que responde à terapia de radiação, e, composição
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
BR0008397A (pt) Processos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo, conjuntos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, e, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo
CY1105634T1 (el) Η χρηση του ραδιου -223 για τη στοχευση ασβεστωμενων ιστων για την ανακουφιση πονου και τη θεραπεια οστικου καρκινου
BR0206985A (pt) Anticorpos modificados e métodos de uso
ATE444019T1 (de) Behandlung von wirbelmetastasen
ES2137554T3 (es) 2-(2-amino-3-metoxifenil)-4-oxo-4h-(1)benzopirano para el tratamiento de desordenes proliferantes.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
BR9912773A (pt) Processo e aparelho para o tratamento tópico de tecido doente e processo para o tratamento de doenças em vasos do sistema circulatório
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
MXPA02009881A (es) Nuevos medicamentos intracorporales para tratamiento fototerapeutico con alta energia de enfermedad.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
BR9504089A (pt) Agente para o tratamento ou cuidado de pele irritada ou inflamada e aplicação
ATE79265T1 (de) Mittel zur behandlung mykotischer, mikrobischer und anderer gewebsschaedigender und pathologischer manifestationen und gewebsdeformationen.
WO2003040725A3 (en) Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.